WO2004100861A2 - Pharmaceutical composition comprising lectin - Google Patents

Pharmaceutical composition comprising lectin Download PDF

Info

Publication number
WO2004100861A2
WO2004100861A2 PCT/BR2004/000070 BR2004000070W WO2004100861A2 WO 2004100861 A2 WO2004100861 A2 WO 2004100861A2 BR 2004000070 W BR2004000070 W BR 2004000070W WO 2004100861 A2 WO2004100861 A2 WO 2004100861A2
Authority
WO
WIPO (PCT)
Prior art keywords
fact
lectin
expression method
relative
figures
Prior art date
Application number
PCT/BR2004/000070
Other languages
French (fr)
Other versions
WO2004100861A3 (en
Inventor
Luis Lamberti Pinto Da Silva
Ademilson Panunto Castelo
Maria Helena De Souza Goldman
Maria Cristina Roque Antunes Barreira
Ricardo Santos De Oliveira
Marcelo Dias Baruffi
Jeanne Blanco De Molfetta Machado
Original Assignee
Fundacão De Amparo À Pesquisa Do Estado De São Paulo - Fapesp
Universidade De São Paulo - Usp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacão De Amparo À Pesquisa Do Estado De São Paulo - Fapesp, Universidade De São Paulo - Usp filed Critical Fundacão De Amparo À Pesquisa Do Estado De São Paulo - Fapesp
Priority to EP04733749A priority Critical patent/EP1635891A2/en
Priority to JP2006529469A priority patent/JP2007528869A/en
Publication of WO2004100861A2 publication Critical patent/WO2004100861A2/en
Publication of WO2004100861A3 publication Critical patent/WO2004100861A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/42Lectins, e.g. concanavalin, phytohaemagglutinin

Definitions

  • the invention deals with a pharmaceutical composition comprising lectin KM+ to prevent and heal epithelial wounds .
  • the invention also comprises the use of lectin
  • KM+ obtained from the plant ⁇ Artocarpus integrifolia ) or recombinant (expression heterologue) to prepare medicaments.
  • Lectins are proteins, or glycoproteins of distribution located in the nature, that if the sugars bind selectively and reversibly.
  • Two lectins had been isolated of seeds of Artocarpus integrifolia (jaca) : jacaline and KM+, also called artocarpine.
  • Lectin KM+ is gotten of the saline extract of seeds of Artocarpus integrifolia.
  • the D-manose is leagued selectively being minority in the saline extract of the seeds (0.5% of total proteins) , contrasting with the high concentration reached for jacaline (30% of total proteins) , ligant lectin of D-galactose, contained in the same saline extract.
  • the crystallization is made it difficult by the small amounts of lectin provided by the purification method, reason for which the three-dimensional structure is proposal for molecular modeling.
  • the attraction of human neutrophils was the first described biological property of KM+. was detected by Saint-of- Oliveira et al . in 1994, through carried through assays in vitro and in alive.
  • the molecular analysis of the phenomenon unchained for the stimulation of neutrophils for the lectin led to the identification of that KM+ recognizes glicanes of cellular surface and that its linking to such glicanes active the cells, inducing its migration for small farms of bigger concentration of lectin.
  • a library of DCNcA from extracted total RNA of jaca seeds was constructed (Artocarpus integrifolia) .
  • the DCNcAs had been donated of directional form in the vector pSPORT-P of the Life Technologies.
  • Such library with approximately 13000 clones was organized in 136 plates of 96 wells (A01 the H12) , contends supply in glicerol of each one of clones. Based in the amino acid sequence of described lectin KM+ for Rose et al.
  • the first plate I contend 96 136 mixtures of clones in each well, was used as source of DNA for the amplification for PCR.
  • the first amplification for PCR was made with oligonucleotides SP6 (for the present sequence in the vector pSPORT-P) and oligol2.
  • SP6 for the present sequence in the vector pSPORT-P
  • oligol2 for the present sequence in the vector pSPORT-P
  • the 28 selected mixtures of clones had been used as source of DNA for an amplification using the oligonucleotides T7 (for the present sequence in the vector pSPORT-P) and oligo 10.
  • the result demonstrated the presence of bands, with the waited size (500 bp or more), in 8 of the analyzed mixtures.
  • Three of these mixtures had been chosen for one third round of analysis, of this time through, the re-amplification of the fragments gotten in first and the second rounds, however with different oligonucleotides (oligos 11 and 12) .
  • Figure 5 shows the alignment of 3 distinct amino acid sequences, corresponding the 3 isoforms of KM+ (one of them gotten through the sequencing of the protein and the others two, amino acid sequences deduced from the sequences of nucleotides of clones pLL29 and pLL30) .
  • Isoforms of the protein KM+, resultants of such forms of heterolog expression, anti-KM+, the selectivity of linking had kept the antigenicity front to the policlonal antibody the D-manose and to the trimanoside Man alfal- 3 [Man alfal-6]Man, when tested front to a panel of sugars.
  • Figure 1 Alignment of the amino acid sequences of lectins KM+ and jacaline.
  • Figure 2 Amino acid sequence of the regions of KM+ chosen for the construction of oligonucleotides.
  • Figure 3 Schematical drawing of the matrix planned, consisting of three plates.
  • Figure 4 Sequence of nucleotides of the present DCNcA of KM+ in the plasmid deduced amino acid pLL29 and sequence
  • Figure 5 Alignment of the amino acid sequences deduced from the DCNcAs of the plasmids pLL29 and pLL30 and the gotten one from chemical analyses of the protein and depositing in data base (Pink et al., 1999).
  • Figure 6 Resultant membrane of the Western blot showing corresponding bands to the recombinant proteins KM+ and produced Gst-km+ in And coli, and protein KM+ produced in S. cerevisiae.
  • Figure 7 Graph that compares the activity of linking with the glycoprotein (peroxidase) exerted by lectin KM+ derived from jaca seeds and by lectin KM+ gotten from the expression in heterologic system (lectin recombinant KM+) .
  • Figure 8 Graph that shows the specific inhibition for monossacaride D-manose of the linking of KM+ of recombinant plant or KM+ to the glycoprotein (peroxidase) .
  • Figure 9 Photographs of decurrent injuries of burnings in the back of rats submitted to the topic application of lectin KM+ or only of the vehicle.
  • the present invention refers it pharmaceutical composition to heal or to prevent epithelial injuries understanding lectin KM+.
  • the invention understands the epithelial injuries holding the cutaneous injuries. Preferential the epithelial injuries understand the injuries of the cornea. More advantageously the invention understands pharmaceutical composition for imunomodulation holding lectin KM+. Still more preferential the invention understands pharmaceutical composition holding lectin KM+. Still more advantageously the invention understands insecticidal composition holding lectin KM+ . Preferential the invention understands medicine holding lectin KM+. Preferential the invention understands insecticide holding lectin KM+. Still more preferential the invention understands the use of lectin KM+ in the imodulator medicine preparation. Advantageously the invention understands the use of lectin KM+ in the medicine preparation to prevent or to deal with decurrent injuries chemical or physical aggressions.
  • the invention understands the use of lectin KM+ in the anti-bacterial medicine preparation. More preferential the invention understands the use of lectin KM+ in the anti-viral medicine preparation. Still more preferential the invention understands the use of lectin KM+ in the anti-parasitic medicine preparation.
  • the invention understands the use of lectin KM+ in the anti-fungal medicine preparation. Still more advantageously the invention understands the use of lectin KM+ in the preparation of insecticide. Still more advantageously the invention understands the use of lectin KM+ in the preparation of insecticidal composition. Preferential the invention understands the use of lectin KM+ for recognition of manose.
  • the invention understands the use of lectin KM+ for purification of proteins contends manose. Still more preferential the invention concerns to the method of expression of lectin KM+ being effected from DCNcA or genomic sequence or synthetic sequence for the native form. Advantageously the invention mentions to it method of expression of lectin KM+ being effected in organism from DCNcA or genomic sequence or synthetic sequence in fusing with other proteins and peptides. More advantageously the method of expression of lectin KM+ can be effected in organism from DCNcA or genomic sequence or synthetic sequence in fusing with peptides.
  • the method of expression of lectin KM+ can be effected in organism from DCNcA or genomic sequence or synthetic sequence in fusing with part of the original protein. Still more advantageously the expression method holds organism understanding procariote or eucariote. Preferential the expression method holds procariote understanding bacteria. More preferential the expression method holds bacteria understanding Escherichia coli. Still more preferential the expression method holds bacteria understanding Caulobacter. Preferential the expression method understands bacteria infectated with recombinant virus . Advantageously the expression method holds eucariote understanding Saccharomyces . More advantageously the expression method holds Saccharomyces understanding S. cerevisiae. Preferential the expression method holds Schizosaccharomyces understanding the S.
  • the expression method holds eucariote understanding Pichia. Still more preferential the expression method holds Pichia understanding the P. search.
  • the expression method holds Pichia understanding the methanolica P. More advantageously the expression method holds eucariote understanding plants. Still more advantageously the expression method understanding transgenics plants.
  • Preferential the expression method understands plants infectated with recombinant virus. More preferential the expression method understands eucariote holding vegetal cells. Still more preferential the expression method holds eucariote understanding animal.
  • the expression method holds animals understanding transgenics. More advantageously the expression method holds animals understanding mammals.
  • the expression method understands the job of mammal cells. More preferential the expression method holds animals understanding insects.
  • the expression method holds eucariote understanding animal transgenics and cells of mammals.
  • the expression method holds eucariote understanding cells of insects.
  • the method of expression of lectin in And coli can be effected from DCNcA subclonado in the vector pDESTl4.
  • the vector of relative DNA understands the Seqs. ID to Figures 1 the 9.
  • the DNA vector understands relative Seq. ID and P F S G P K to Figures 1 the 9.
  • the DNA vector understands relative Seq. ID K L P Y K N to Figures 1 and 9.
  • the DNA vector understands Seq ID relative I G V H M to Figures 1 the 9.
  • the vector I contend the gene of the lectin understands the Seqs.
  • the recombinant organism understands the Seqs.
  • the recombinant organism understands the Seqs.
  • the DNA sequence can make pareament with the Seq. ID. relatives to Figures 1 the 9.
  • the sequence of nucleotides can codify one of the amino acid sequences of lectin KM+.
  • the lectin protein of Artocarpus integrifolia mentions the Seqs to it.
  • Relative- ID to Figures 1 the 9.
  • the lectin protein of Artocarpus integrifolia mentions the Seqs to it.
  • Relative ID to cited Figures 1 the 9 and any of isoforms.
  • the lectin protein of Artocarpus integrifolia mentions the Seqs to it.
  • Relative ID to cited Figures 1 the 9 and any of isoforms.
  • the method of expression of lectin KM+ in S . cerevisiae can be effected from DCNcA subclonado in the vector pYES-DEST52.
  • the plasmid of expression can contain as inserto the DNA sequence that codifies for lectin protein KM+ of Artocarpus integrifolia. More advantageously the plasmid of expression can use the relative information to the gene of lectin KM+ of Artocarpus integrifolia.
  • mice daily pay-inoculated with KM+ showed size and significantly lesser number of granulomes how much to not treated.
  • Such results indicate that KM+ intervenes positively with the course of the infection for P.brasiliensis, and that such imunomodulatory effect if makes independently of any process of immunization with fungic antigen.
  • Lectin KM+ was incorporated in ointment on the basis of petroleum jelly, added or not of acid linoleic and also in formularization the base of propilenoglicol .
  • the incorporation can be made in conventional dermatological bases (remarcably emulsions water in oil, hydrophilic and gel emulsions oil in water, ointment hidrofobics, ointment) , as well as in elaborated systems of release more, contends or not promotional substances of the cutaneous absorption (remarcably propilenoglicol, acid oleic, derivatives of pirrolidona, etanol, dimetilsulf ⁇ xido, and fosfolipides) as multiple emulsions, micron and nanoemulsion or emulsions sucr ⁇ micas, lipossomes, transferssomes, ethossomes and other types of vesicles, nanossomes, beyond other micron and nanoparticulados systems, as micron and nanocapsules, micron and nanoespheres and vehicles I contend ceramides, liquid, complex crystals of inclusion as that one with ciclodextrines, supersaturated solutions, formular
  • transdermic powderject it shoots particles through the corneo stratum for the layers deepest of the skin for supersonic waves of gas shock helium
  • intraject uses gas source compressed nitrogen to project doses of formularization through the skin for the fabric subcutaneous
  • microneedles iontoforese, eletroporaction and high voltage (100 the 1000 V)
  • sonoforese The acute influx of inflammatory cells for KM+ based the hypothesis of that the lectin could have anti-microbian action to the being applied in injured cutaneous surfaces that, as well known, correspond the important door of entrance of patogens .
  • the secondary infection corresponds the cause most frequent of death of patients with extensive losses of continuity of the cutaneous surface, as the ones that occur in great burnt.
  • rats had been submitted the thermal aggression in the dorsal region and topically treated with ointment I contend KM+.
  • Surprising the action of KM+ if it made to after notice since few hours the application of the ointment one, and it was not related with the combat to the secondary infections, but yes to a precocious regeneration of the fabric injured.
  • the animals dealt with KM+ differentiated themselves of the not treat ones (to which the vehicle was applied only) for the absence of necro-hemorrhagic areas, or deep injuries that they displayed weaved muscular. In contrast regeneration if made quickly, the edges of the injuries was little salient, was come close quickly, having precocious cicatrizaction of the wound, manifest for local reepitelizaction and ressurgiment of pilificaction. Many experiments, of varied characteristics had been repeated, with superficial or deep injuries, different burnings of ample or small diameters, times of exposition to the heat, use of dry or humid heat.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention deals with a pharmaceutical composition comprising lectin KM+ to prevent and heal epithelial wounds. The invention also comprises the use of lectin KM+, obtained from the plant Artocarpus integrifolia or the use of recombinant lectin to prepare medicaments.

Description

PHARMACEUTICAL COMPOSITION TO PREVENT AND TREAT EPITHELIAL WOUNDS, IMMUNOMODULATING PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMPOSITION, INSECTICIDE, INSECTICIDE COMPOSITION, INSECTICIDE USE OF LECTIN KM+ TO TREAT CICATRIZATIONS, USE OF LECTIN KM+ TO PREPARE IMMUNOMODULATING MEDICAMENT, USE OF LECTIN KM+ TO PREPARE ANTI-BACTERIAL MEDICAMENT, USE LECTIN KM+ TO PREPARE ANTI-VIRAL MEDICAMENT, USE OF LECTIN KM+ TO PREPARE ANTI- PARASITE MEDICAMENT, USE OF LECTIN KM+ TO PREPARE ANTI-FUNGAL MEDICAMENT, USE OF LECTIN KM+ TO PREPARE ANTI-PARASITE MEDICAMENT EXPRESSION METHOD, DNA VECTOR, RECOMBINANT ORGANISM, SEQUENCE OF NUCLEOTIDES, ANTIBODY, PROTEINS AND PLASMIDS
The invention deals with a pharmaceutical composition comprising lectin KM+ to prevent and heal epithelial wounds . The invention also comprises the use of lectin
KM+, obtained from the plant {Artocarpus integrifolia ) or recombinant (expression heterologue) to prepare medicaments.
Lectins are proteins, or glycoproteins of distribution located in the nature, that if the sugars bind selectively and reversibly. Two lectins had been isolated of seeds of Artocarpus integrifolia (jaca) : jacaline and KM+, also called artocarpine. Lectin KM+ is gotten of the saline extract of seeds of Artocarpus integrifolia. The D-manose is leagued selectively being minority in the saline extract of the seeds (0.5% of total proteins) , contrasting with the high concentration reached for jacaline (30% of total proteins) , ligant lectin of D-galactose, contained in the same saline extract. Related studies to lectin KM+ mention the standardization to it of method for its purification, made from the saline extract of the seeds for chromatography of affinity in columns of immobilized sugar in two stages. In the first o extract it is depleted of jacaline for adsortion to the immobilized D-galactose. To follow the depleted extract it with solution of D-manose is cromatographated in column of D-manose, eluded itself on lectin. The method provides homogeneous preparations of the lectin, that had been used in the determination of its primary structure and in the attempt of crystal attainment for determination of the structure 3-D of the protein. The crystallization is made it difficult by the small amounts of lectin provided by the purification method, reason for which the three-dimensional structure is proposal for molecular modeling. The attraction of human neutrophils was the first described biological property of KM+. was detected by Saint-of- Oliveira et al . in 1994, through carried through assays in vitro and in alive. The molecular analysis of the phenomenon unchained for the stimulation of neutrophils for the lectin, led to the identification of that KM+ recognizes glicanes of cellular surface and that its linking to such glicanes active the cells, inducing its migration for small farms of bigger concentration of lectin. The movement of neutrophil induced for KM+ if gives for haptotaxy, made possible for the fact of the lectin to be tetravalent, the domains of recognition of KM+ sugar form a bridge enter the surface of neutrophil and the laminine glycoprotein of the extracellular matrix. The ideal conditions for an adjusted cellular movement are established thus. This model of interactions revealed applicable for the induction of induced cellular movement for endogenous lectins, as galectin-3 and MNCF, as Dias-Baruffi et al, 1999. The comment of that the interaction of KM+ with glicanes of neutrofilic surface is capable to unchain dependent answers of cellular signaling, led to the assumption of that the lectin could activate other immunitary cells and of this way to correspond to adjuvant an interesting one in immunization processes. It was verified initially that cells of the peritoneal socket of mice produced great amount of interferon gamma under stimulation of KM+, and that such production was indirectly induced for the secretated 11-12 in high concentrations for the linking of KM+ to the surface of the macrophages, contained in the preparation of peritoneal cells. As such profile of citocines it is compatible with the establishment of imunitary answers of standard TH1, was opted to investigating the benefit eventually brought by the use of KM+ as adjuvant in the immunization against a sensible patogen answers THl . The chosen model was of infection for Leishmania the major of mice of highly susceptible race to the patogen (BALB/c)-. Previously to the infection the animals had been inoculated with a soluble antigen preparation of Leishmania (SLA) associate, or not it KM+. The study with L. major it showed that the animals that had received KM+ had substituted the standard of susceptibility for a standard of resistance to the parasite, as well as had inverted standard TH2 of citocines produced for a profile TH1. Thus the KM+ administration can intervine in a imunitarie reply of form to become it efficient against certain types of patogens . A time that this independent effect of the concomitant administration of the parasitic antigen, was transferred to consider it that KM+ is endowed with imunomodulator property, instead of adjuvant. As the rigorous purification of KM+ provided low income and that the excellent biological properties of KM+ imposed biotechnological investments that made possible its application in ample scale, it was opted to proceeding the clonage and characterization from the DCNcA that codifies the lectin, aiming at to arrive the recombinant form of this lectin, through its heterolog expression. Such availability of recombinant lectin makes possible its application as therapeutical agent in injuries for burnings, as well as cicatrizant of injuries of diverse nature, as well as other pharmaceutical and/or biotechnological uses. A library of DCNcA from extracted total RNA of jaca seeds was constructed (Artocarpus integrifolia) . The DCNcAs had been donated of directional form in the vector pSPORT-P of the Life Technologies. Such library, with approximately 13000 clones was organized in 136 plates of 96 wells (A01 the H12) , contends supply in glicerol of each one of clones. Based in the amino acid sequence of described lectin KM+ for Rose et al. (1999), and in the alignment of amino acid sequences of jacaline lectins and KM+ (Figure 1) , had been defined regions of KM+, distinct of jacaline, for which they had been drawn oligonucleotides depraved (oligo 10, oligo 11 and oligo 12, Figure 2) . The election of the library of DCNcA of jaca seeds was carried through by PCR of matrix, from the mixture commanded of clones of DCNcA (mixture of the 136 clones in the A01 position, of the 136 clones of the A02 position and thus successively, until the 136 mixture of clones of the H12 position. The first plate I contend 96 136 mixtures of clones in each well, was used as source of DNA for the amplification for PCR. The first amplification for PCR was made with oligonucleotides SP6 (for the present sequence in the vector pSPORT-P) and oligol2. Of the result of the 96 amplifications, analyzed for eletroforese in gel of agarose, 28 reactions, that had produced a band of equal or superior size the 500 pairs of bases (bp) , for one second round of analysis had been selected. The 28 selected mixtures of clones had been used as source of DNA for an amplification using the oligonucleotides T7 (for the present sequence in the vector pSPORT-P) and oligo 10. The result demonstrated the presence of bands, with the waited size (500 bp or more), in 8 of the analyzed mixtures. Three of these mixtures had been chosen for one third round of analysis, of this time through, the re-amplification of the fragments gotten in first and the second rounds, however with different oligonucleotides (oligos 11 and 12) . The amplification from the 3 mixtures (position E07, G07 and F08) resulted in the appearance of a band of waited size and confirmed the presence of clones of DCNcA for K +, in each one of the 3 mixtures. Of the 136 original plates, I contend only one clone of DCNcA in each well, had been removed aliquot of the supply in glicerol, that, in turn, they had served to initiate cultures in a new plate of 96 wells. In this stage, only clones in the positions E07 and F07 had been used (F08 was not analyzed to simplify the work) . The 136 clones of the E07 position and the 136 clones of the F07 position had been reorganized in new plates, that had again served as starting point for the assembly of a new matrix. This second matrix resulted of the mixture of all clones placed in one same line or one same column, in a total of 36 mixtures (Figure 3) . These mixtures had been used as source of DNA for an amplification for PCR using the oligos T7 and 11. The result of the amplifications allowed to define the position of clones of DCNcA for KM+ (A*12 or pLL30 and E*01 or pLL29) , that they had been removed of the plates of the original library and had been used for the preparation of DNA and sequencing (Figure 4) . Figure 5 shows the alignment of 3 distinct amino acid sequences, corresponding the 3 isoforms of KM+ (one of them gotten through the sequencing of the protein and the others two, amino acid sequences deduced from the sequences of nucleotides of clones pLL29 and pLL30) . Isoforms of the protein KM+, resultants of such forms of heterolog expression, anti-KM+, the selectivity of linking had kept the antigenicity front to the policlonal antibody the D-manose and to the trimanoside Man alfal- 3 [Man alfal-6]Man, when tested front to a panel of sugars. In alive and in had been also capable to induce the migration of neutrophils vitro and to induce murines peritoneal cells to produce citocines of standard TH1. The following figures are part of the asked for gift: Figure 1: Alignment of the amino acid sequences of lectins KM+ and jacaline. Figure 2: Amino acid sequence of the regions of KM+ chosen for the construction of oligonucleotides. Figure 3: Schematical drawing of the matrix planned, consisting of three plates. Figure 4: Sequence of nucleotides of the present DCNcA of KM+ in the plasmid deduced amino acid pLL29 and sequence Figure 5: Alignment of the amino acid sequences deduced from the DCNcAs of the plasmids pLL29 and pLL30 and the gotten one from chemical analyses of the protein and depositing in data base (Pink et al., 1999). Figure 6: Resultant membrane of the Western blot showing corresponding bands to the recombinant proteins KM+ and produced Gst-km+ in And coli, and protein KM+ produced in S. cerevisiae. Figure 7: Graph that compares the activity of linking with the glycoprotein (peroxidase) exerted by lectin KM+ derived from jaca seeds and by lectin KM+ gotten from the expression in heterologic system (lectin recombinant KM+) . Figure 8: Graph that shows the specific inhibition for monossacaride D-manose of the linking of KM+ of recombinant plant or KM+ to the glycoprotein (peroxidase) . Figure 9: Photographs of decurrent injuries of burnings in the back of rats submitted to the topic application of lectin KM+ or only of the vehicle. The present invention refers it pharmaceutical composition to heal or to prevent epithelial injuries understanding lectin KM+. Advantageously it understands the epithelial injuries holding the cutaneous injuries. Preferential the epithelial injuries understand the injuries of the cornea. More advantageously the invention understands pharmaceutical composition for imunomodulation holding lectin KM+. Still more preferential the invention understands pharmaceutical composition holding lectin KM+. Still more advantageously the invention understands insecticidal composition holding lectin KM+ . Preferential the invention understands medicine holding lectin KM+. Advantageously the invention understands insecticide holding lectin KM+. Still more preferential the invention understands the use of lectin KM+ in the imodulator medicine preparation. Advantageously the invention understands the use of lectin KM+ in the medicine preparation to prevent or to deal with decurrent injuries chemical or physical aggressions. More advantageously the invention understands the use of lectin KM+ in the anti-bacterial medicine preparation. More preferential the invention understands the use of lectin KM+ in the anti-viral medicine preparation. Still more preferential the invention understands the use of lectin KM+ in the anti-parasitic medicine preparation. Advantageously the invention understands the use of lectin KM+ in the anti-fungal medicine preparation. Still more advantageously the invention understands the use of lectin KM+ in the preparation of insecticide. Still more advantageously the invention understands the use of lectin KM+ in the preparation of insecticidal composition. Preferential the invention understands the use of lectin KM+ for recognition of manose. More preferential the invention understands the use of lectin KM+ for purification of proteins contends manose. Still more preferential the invention concerns to the method of expression of lectin KM+ being effected from DCNcA or genomic sequence or synthetic sequence for the native form. Advantageously the invention mentions to it method of expression of lectin KM+ being effected in organism from DCNcA or genomic sequence or synthetic sequence in fusing with other proteins and peptides. More advantageously the method of expression of lectin KM+ can be effected in organism from DCNcA or genomic sequence or synthetic sequence in fusing with peptides. Preferential the method of expression of lectin KM+ can be effected in organism from DCNcA or genomic sequence or synthetic sequence in fusing with part of the original protein. Still more advantageously the expression method holds organism understanding procariote or eucariote. Preferential the expression method holds procariote understanding bacteria. More preferential the expression method holds bacteria understanding Escherichia coli. Still more preferential the expression method holds bacteria understanding Caulobacter. Preferential the expression method understands bacteria infectated with recombinant virus . Advantageously the expression method holds eucariote understanding Saccharomyces . More advantageously the expression method holds Saccharomyces understanding S. cerevisiae. Preferential the expression method holds Schizosaccharomyces understanding the S. pombe. More preferential the expression method holds eucariote understanding Pichia. Still more preferential the expression method holds Pichia understanding the P. pastoral. Advantageously the expression method holds Pichia understanding the methanolica P. More advantageously the expression method holds eucariote understanding plants. Still more advantageously the expression method understanding transgenics plants. Preferential the expression method understands plants infectated with recombinant virus. More preferential the expression method understands eucariote holding vegetal cells. Still more preferential the expression method holds eucariote understanding animal. Advantageously the expression method holds animals understanding transgenics. More advantageously the expression method holds animals understanding mammals. Preferential the expression method understands the job of mammal cells. More preferential the expression method holds animals understanding insects. Still more preferential the expression method holds eucariote understanding animal transgenics and cells of mammals. Advantageously the expression method holds eucariote understanding cells of insects. Preferential the method of expression of lectin in And coli, can be effected from DCNcA subclonado in the vector pDESTl4. More preferential the vector of relative DNA understands the Seqs. ID to Figures 1 the 9. Advantageously the DNA vector understands relative Seq. ID and P F S G P K to Figures 1 the 9. Advantageously the DNA vector understands relative Seq. ID K L P Y K N to Figures 1 and 9. Advantageously the DNA vector understands Seq ID relative I G V H M to Figures 1 the 9. Still more advantageously the vector I contend the gene of the lectin understands the Seqs. Relative ID to Figures 1 the 9. Preferential the recombinant organism understands the Seqs. Relative ID to Figures 1 the 9. More preferential the recombinant organism contains part of this protein. Advantageously the DNA sequence can make pareament with the Seq. ID. relatives to Figures 1 the 9. Preferential the sequence of nucleotides can codify one of the amino acid sequences of lectin KM+. More preferential the lectin protein of Artocarpus integrifolia mentions the Seqs to it. Relative- ID to Figures 1 the 9. Advantageously the lectin protein of Artocarpus integrifolia mentions the Seqs to it. Relative ID to cited Figures 1 the 9 and any of isoforms. Preferential the lectin protein of Artocarpus integrifolia mentions the Seqs to it. Relative ID to cited Figures 1 the 9 and any of isoforms. More preferential the method of expression of lectin KM+ in S . cerevisiae, can be effected from DCNcA subclonado in the vector pYES-DEST52. Advantageously the plasmid of expression can contain as inserto the DNA sequence that codifies for lectin protein KM+ of Artocarpus integrifolia. More advantageously the plasmid of expression can use the relative information to the gene of lectin KM+ of Artocarpus integrifolia. Observing itself that lectin KM+, through the property to induce macrophages to produce 11-12 and to exert protective effect against infection for L. major and knowing itself that the brasiliensis resistance to the infection for Paracoccidioides depends on an efficient Thl reply, evaluated the effect of the inoculation of KM+ in mice that would be defied with leavenings of P. brasiliensis. Groups of animals had been injected with KM+, associate or not its cell free antigen (CFA) proceeding from isolated Pb 18 of P. brasiliensis. Animals of another group had been injected with alone CFA and a group control received PBS. The animals intravenously had been infectated with isolated leavenings of virulent of P.brasiliensis and, in the following period, monitored how much the diverse parameters, including the proliferactive reply of esplenic cells, recovery of formator units of colonies (CFU) in the fabric pulmonary and histopatologye of pulmonary injuries. The depression of proliferactive, proper reply of the infection, was reverted in the animals daily pay-inoculated with KM+. The recovery of formator units of colonies in the fabric pulmonary was carried through and was verified that the proportionate amount of colonies for the lungs of the animals daily pay-inoculated with KM+, was very inferior to the gotten one in the lungs of the animals that had not received the lectin. The pulmonary histopatologye showed that the mice daily pay-inoculated with KM+ showed size and significantly lesser number of granulomes how much to not treated. Such results indicate that KM+ intervenes positively with the course of the infection for P.brasiliensis, and that such imunomodulatory effect if makes independently of any process of immunization with fungic antigen. Lectin KM+ was incorporated in ointment on the basis of petroleum jelly, added or not of acid linoleic and also in formularization the base of propilenoglicol . The incorporation can be made in conventional dermatological bases (remarcably emulsions water in oil, hydrophilic and gel emulsions oil in water, ointment hidrofobics, ointment) , as well as in elaborated systems of release more, contends or not promotional substances of the cutaneous absorption (remarcably propilenoglicol, acid oleic, derivatives of pirrolidona, etanol, dimetilsulfόxido, and fosfolipides) as multiple emulsions, micron and nanoemulsion or emulsions sucrδmicas, lipossomes, transferssomes, ethossomes and other types of vesicles, nanossomes, beyond other micron and nanoparticulados systems, as micron and nanocapsules, micron and nanoespheres and vehicles I contend ceramides, liquid, complex crystals of inclusion as that one with ciclodextrines, supersaturated solutions, formularizations with macro-molecules capable to form gel and films. To improve still more the penetration they could be gotten pro-pharmaceuticals of the substance (as ester remarcably) , leaving it with a rocking hidro and adjusted lipophilic more for the penetration in the followed corneo stratum of conversion in the skin for the free pharmaceutical. All these pharmaceutical forms and systems of release of the pharmaceutical can be placed in devices that still more improve the performance of the substance for determined required action, as, remarcably, transdermic powderject (it shoots particles through the corneo stratum for the layers deepest of the skin for supersonic waves of gas shock helium) intraject (uses gas source compressed nitrogen to project doses of formularization through the skin for the fabric subcutaneous), microneedles, iontoforese, eletroporaction and high voltage (100 the 1000 V), sonoforese. The acute influx of inflammatory cells for KM+ based the hypothesis of that the lectin could have anti-microbian action to the being applied in injured cutaneous surfaces that, as well known, correspond the important door of entrance of patogens . The secondary infection corresponds the cause most frequent of death of patients with extensive losses of continuity of the cutaneous surface, as the ones that occur in great burnt. To test the hypothesis of that the influx of neutrophils provoked by the lectin could diminish the infection incidence, rats had been submitted the thermal aggression in the dorsal region and topically treated with ointment I contend KM+. Surprising the action of KM+ if it made to after notice since few hours the application of the ointment one, and it was not related with the combat to the secondary infections, but yes to a precocious regeneration of the fabric injured. The animals dealt with KM+ differentiated themselves of the not treat ones (to which the vehicle was applied only) for the absence of necro-hemorrhagic areas, or deep injuries that they displayed weaved muscular. In contrast regeneration if made quickly, the edges of the injuries was little salient, was come close quickly, having precocious cicatrizaction of the wound, manifest for local reepitelizaction and ressurgiment of pilificaction. Many experiments, of varied characteristics had been repeated, with superficial or deep injuries, different burnings of ample or small diameters, times of exposition to the heat, use of dry or humid heat. In all the experimental circumstances the animals if had benefited of the local application of KM+ In Figure 9 are the photographs of the dorsal region of two groups of animals, 5 treated topically with lectin KM+ (3 applications) , and treated others 5 only with the vehicle (3 applications) . All had suffered to thermal injury in the back 24 hours before the photo. The rats dealt with KM+
(inferior photograph series) had had the fabric preserved, while the ones that had received only the vehicle (superior photograph series) present local necro-hemorrhagic injuries. The dramatical beneficial action of the application of KM+ in the fabrics is clear that had suffered thermal aggression.

Claims

I. Pharmaceutical composition to prevent the appearance of epithelia wounds, characterized by the fact of containing lectin KM+.
2. Pharmaceutical composition to treat epithelia wounds, characterized by the fact of containing lectin KM+.
3. Pharmaceutical composition according to any of claims 1 or 2, characterized by the fact that the epithelia wounds comprise skin wounds.
4. Pharmaceutical composition according to any of claims 1 or 2, characterized by the fact that the epithelia wounds comprise cornea wounds.
5. Pharmaceutical composition for immunomodulating, characterized by the fact of containing lectin KM+.
6. Pharmaceutical composition characterized by the fact of containing lectin KM+.
7. Insecticide characterized by the fact of containing lectin KM+.
8. Medicament characterized for containing lectin
KM+.
9. Insecticide characterized for containing lectin KM+ .
10. Use of lectin KM+ characterized for being in the preparation of medicaments to treat wounds, as a cicatriser.
II. Use of lectin KM+ characterized for being in the preparation of immunomodulating medicaments.
12. Use of lectin KM+ characterized for being in the preparation of medicaments to prevent wounds resulting from chemical or physical aggressions.
13. Use of lectin KM+ characterized for being in the preparation of anti-bacterial medicament.
14. Use of lectin KM+ characterized for being in the preparation of anti-viral medicament.
15. Use of lectin KM+ characterized for being in the preparation of anti-parasite medicament.
16. Use of lectin KM+ characterized for being in the preparation of anti-fugal medicament.
17. Use of lectin KM+ characterized for being in the preparation of insecticide.
18. Use of lectin KM+ characterized for being in the preparation of manose.
19. Use of lectin KM+ characterized for being in the purification or detection of proteins containing manose.
20. Lectin KM+ expression method characterized by the fact of being carried out in organism from cDNA or genomic sequence or synthetic sequence in the native form.
21. Lectin KM+ expression method characterized by the fact of being carried out in organism from cDNA or genomic sequence or synthetic sequence fused with other proteins and peptides.
22. Lectin KM+ expression method characterized by the fact of being carried out in organism from cDNA or genomic sequence or synthetic sequence fused with peptides.
23. Lectin KM+ expression method characterized by the fact of being carried out in organism from cDNA or genomic sequence or synthetic sequence fused with part of the original protein.
24. Expression method according to any of claims 20 a 23, characterized by the fact that the organism comprises prokaryote or eukaryote .
25. Expression method according to claim 24 characterized by the fact that the prokaryote comprises bacteria.
26. Expression method according to claim 25 characterized by the fact that the bacteria comprise Escherichia coll .
27. Expression method according to claim 25, characterized by the fact that the bacteria comprise Caulobacter.
28. Expression method according to claim 25, characterized by the fact that the bacteria are infected with recombinant virus .
29. Expression method according to claim 24 characterized by the fact that the eukaryotes comprise Saccharomyces .
30. Expression method according to claim 28, characterized by the fact that the Sa ccharomyces comprises s . cerev±siae .
31. Expression method according to claim 28, characterized by the fact that the Schizosaccharomyces comprises S . pombe .
32. Expression method according to claim 24, characterized by the fact that the eukaryote comprises Pichia .
33. Expression method according to claim 31, characterized by the fact that the Pichia comprises P. pastoris.
34. Expression method according to claim 31, characterized by the fact that the Pichia comprises P. methanolica .
35. Expression method according to claim 24, characterized by the fact that the eukaryote comprises plants.
36. Expression method according to claim 34, characterized by the fact that the plants are transgenic.
37. Expression method according to claim 35, characterized by the fact that the plants are infected with recombinant virus.
38. Expression method according to claim 24, characterized by the fact that the eukaryote comprises vegetable cells .
39. Expression method according to claim 24, characterized by the fact that the eukaryote comprises animal cells .
40. Expression method according to claim 38, characterized by the fact that the animals comprise transgenic.
41. Expression method according to any claim 38 or 39, characterized by the fact that the animals comprise mammals .
42. Expression method according to claim 40, characterized by the fact that mammal cells are used.
43. Expression method according to claim 38, characterized by the fact that the animals comprise insects.
44. Expression method according to claim 24, characterized by the fact that the eukaryote comprises transgenic animals and mammal cells.
45. Expression method according to claim 24, characterized by the fact that the eukaryote comprises insect cells .
46. Lectin expression method in E . coli , characterized by the fact of being carried out from subcloned cDNA in pDESTl4 vector.
47. DNA vector characterized for comprising Seqs. ID relative to Figures 1 to 9.
48. DNA vector according to claim 46, characterized by the fact that Seq. ID relative to Figures 1 to 9 is E P F S G P K.
49. DNA vector according to claim 46, characterized by the fact that Seq. ID relative to Figures 1 to 9 is K L P Y K N.
50. DNA vector according to claim 46, characterized by the fact that Seq. ID relative to Figures 1 to 9 is A I G V H M A.
51. Vector containing the lectin gene, characterized by comprising Seqs. ID relative to Figures 1 to 9.
52. Recombinant organism characterized by comprising Seqs. ID relative to Figures 1 to 9.
53. Recombinant organism according to claim 51, characterized by the fact of containing part of this protein.
54. DNA sequence characterized for pairing of with Seqs. ID. relative to Figures 1 to 9.
55. Nucleotide sequence characterized for codifying one of the lectin KM+ aminoacid sequences.
56. Lectin protein of Artocarpus integrifolia characterized for comprising Seqs. ID relative to Figures 1 to 9.
57. Lectin protein of Artocarpus integrifolia characterized for comprising Seqs. ID relative to Figures 1 to 9 and its isoforms.
58. Lectin protein of Artocarpus integrifolia according to any claims 55 or 56 characterized by the fact that Seq. ID relative to Figures 1 to 9 is E P F S G P K.
59. Lectin protein of Artocarpus integrifolia according to any claims 55 or 56 characterized by the fact that
Seq. ID relative to Figures 1 to 9 is K L P Y K N.
60. Lectin protein of Artocarpus integrifolia according to any claims 55 or 56 characterized by the fact that Seq. ID relative to Figures 1 to 9 is A I G V H M A.
61. Lectin KM+ expression method in S. cerevisiae, characterized by the fact of being carried out characterized by the fact of being carried out from subcloned cDNA in pYES-DEST52.
62. Vector expression plasmid characterized by the fact of containing as unsure the DNA sequence that codifies for the lectin KM+ protein of Artocarpus integrifolia .
63. Expression plasmid according to claim 61, characterized by the fact of using information relative to the lectin KM+ gene of Artocarpus integrifolia .
PCT/BR2004/000070 2003-05-19 2004-05-19 Pharmaceutical composition comprising lectin WO2004100861A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04733749A EP1635891A2 (en) 2003-05-19 2004-05-19 Pharmaceutical composition to prevent and treat epithelial wounds, immunomodulating pharmaceutical composition, pharmaceutical composition, insecticide, insecticide composition, insecticide use of lectin km+ to treat cicatrizations, use of lectin km+ to prepare immunomodulating medicament
JP2006529469A JP2007528869A (en) 2003-05-19 2004-05-19 Pharmaceutical composition for epithelial wound prevention and treatment, immunoregulatory pharmaceutical composition, pharmaceutical composition, insecticide, insecticide composition, use of insecticide of lectin KM + in the treatment of scarring, use of lectin KM + in preparation of immunoregulatory drug , Use of lectin KM + in formulating antibacterial drugs, use of lectin KM + in formulating antiviral drugs, use of lectin KM + in formulating antifungal drugs, use of lectin KM + in formulating antiparasitic drugs, expression methods, DNA vectors, recombinant organisms , Nucleotide sequences, antibodies, proteins and extranuclear genes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRC10301547-5A BR0301547C1 (en) 2003-05-19 2003-05-19 pharmaceutical composition for treating fungal pathology comprising km + lectin, pharmaceutical composition for preventing fungal pathology comprising km + lectin, use of km + lectin for preparing medicine for treating fungal pathology, use of km + lectin for preparing medicine for preventing fungal pathology
BRPI0301547-5 2003-05-19

Publications (2)

Publication Number Publication Date
WO2004100861A2 true WO2004100861A2 (en) 2004-11-25
WO2004100861A3 WO2004100861A3 (en) 2006-12-07

Family

ID=37744501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2004/000070 WO2004100861A2 (en) 2003-05-19 2004-05-19 Pharmaceutical composition comprising lectin

Country Status (5)

Country Link
EP (1) EP1635891A2 (en)
JP (1) JP2007528869A (en)
AR (1) AR044389A1 (en)
BR (1) BR0301547C1 (en)
WO (1) WO2004100861A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2914858A1 (en) * 2007-04-13 2008-10-17 Lucas Meyer Cosmetics Sa Topical cosmetic composition useful e.g. as depigmenting agent, capillary growth activator and to treat pigmentary spots, comprises vegetable lectin or vegetable extract rich in lectin having inhibiting activity of melanosome phagocytosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020001600A1 (en) * 1995-05-30 2002-01-03 Michael J. Oldham Method of using lectins for prevention and treatment of skin diseases and disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PEREIRA DA SILVA ET AL., IMMUNOLOGY LETTERS, vol. 119, 2008, pages 114 - 115
ROSA ET AL., PROTEIN SCIENCE, vol. 8, 1999, pages 13 - 24

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2914858A1 (en) * 2007-04-13 2008-10-17 Lucas Meyer Cosmetics Sa Topical cosmetic composition useful e.g. as depigmenting agent, capillary growth activator and to treat pigmentary spots, comprises vegetable lectin or vegetable extract rich in lectin having inhibiting activity of melanosome phagocytosis

Also Published As

Publication number Publication date
WO2004100861A3 (en) 2006-12-07
EP1635891A2 (en) 2006-03-22
AR044389A1 (en) 2005-09-07
BR0301547A (en) 2005-03-22
BR0301547C1 (en) 2007-02-21
JP2007528869A (en) 2007-10-18

Similar Documents

Publication Publication Date Title
Dotimas et al. Honeybee venom
She et al. A novel lectin with potent immunomodulatory activity isolated from both fruiting bodies and cultured mycelia of the edible MushroomVolvariella volvacea
TWI232222B (en) Fungal antigens, process for producing the same and composition contain the same
King et al. Inflammatory role of two venom components of yellow jackets (Vespula vulgaris): a mast cell degranulating peptide mastoparan and phospholipase A1
US10548945B2 (en) Topical compositions comprising OB-fold variants
CN105106945B (en) A kind of helicobacter pylori tetravalence virulence factor polyepitope vaccines and preparation method thereof
Shen et al. Expression of recombinant AccMRJP1 protein from royal jelly of Chinese honeybee in Pichia pastoris and its proliferation activity in an insect cell line
Johnson et al. RELATIONSHIP OF STRUCTURE TO FUNCTION IN BACTERIAL O ANTIGENS: III. Biological Properties of Endotoxoids
US20070105754A1 (en) Pharmaceutical composition to prevent and treat epithelial wounds, immunomodulating pharmaceutical composition, pharmaceutical composition, insecticide, insecticide composition insecticide use of lectin KM+ to treat cicatrizations, use of lectin KM+ to prepare immunomodulating medicament, use of lectin KM+ to prepare anti-bacterial medicament, use lectin KM+ to prpare anti-viral medicament, use of lectin KM+ to prepare anti-parasite medicament, use of lectin KM+ to prepare anti-fungal medicament, use of lectin KM+ to prepare anti-parasite medicament expression method, DNA vector, recombinant
Watson et al. Studies on Infection with Bacillus anthracis: V. The Isolation of an Inflammatory Factor from Crude Extracts of Lesions of B. anthracis Infection and Its Biological and Chemical Relationship to Glutamyl Polypeptide
Kong et al. Delayed dermal hypersensitivity in mice to spherule and mycelial extracts of Coccidioides immitis
CN106868025A (en) The method that tripolymer Ebola virus glycoproteins mutant is prepared with yeast
US20210054035A1 (en) Transdermal peptide with nuclear localization ability and use thereof
EP1635891A2 (en) Pharmaceutical composition to prevent and treat epithelial wounds, immunomodulating pharmaceutical composition, pharmaceutical composition, insecticide, insecticide composition, insecticide use of lectin km+ to treat cicatrizations, use of lectin km+ to prepare immunomodulating medicament
Ford et al. Schwann cells are able to present exogenous mycobacterial hsp70 to antigen-specific T lymphocytes
CN107904251B (en) Preparation of TAT-hEGF fusion protein and application of TAT-hEGF fusion protein in invisible mask
CN106692963A (en) Combined vaccine for preventing staphylococcus aureus infection and tetanus
EP1768996A1 (en) Variants of group 1 allergens of poaceae with reduced allergenicity and a maintained t-cell reactivity
ES2964122T3 (en) Extract and dermatological composition that contains it for the treatment of sensitive skin
CN105622734A (en) Method for purifying pseudomonas aeruginosa vaccine recombinant protein Vac 14
CN112029802A (en) Preparation method and application of exosome rich in human keratinocyte growth factor-2
CN1904041B (en) Human recombination phospholipase D2, its preparation method and application in preparation medicine
KR102596264B1 (en) Composition for Inhibiting Inflammatory Disease Comprising Biocompatible Polypeptide Connected to Functional Peptide
CN102690342A (en) Anti-cancer analgesic peptide VKVR, its preparation method and application
US6372219B1 (en) Parasite-derived anti-inflammatory immunomodulatory protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006529469

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004733749

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004733749

Country of ref document: EP